@dr.karanr's GLP-1 weight surgery claims, fact-checked

What did @dr.karanr actually say?

The video argues that a drug could mean "the end of weight loss surgery" after a major trial showed participants losing "more than a fifth of their body weight." The creator names the drug as "temroglutide" and says it works by "hijacking the body's appetite levels" and mimicking a hormone called GLP-1. The trial involved almost 2,000 people and showed an average "15 kilowatt loss" over 15 months.

There is a lot packed into a short clip, and some of it is genuinely accurate. But there are also errors significant enough to change how a patient might interpret the results, and the framing of surgery being "ended" by this drug is not what the evidence shows.

Does the science back this up?

The trial being described is almost certainly the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), which studied semaglutide 2.4mg weekly in 1,961 adults with obesity. Participants did lose a substantial amount of weight, with an average of around 14.9% of body weight over 68 weeks. That is a real and clinically meaningful result that no honest observer should dismiss.

The GLP-1 mechanism is also accurately described in broad terms. Semaglutide does mimic glucagon-like peptide-1, a gut hormone that slows gastric emptying and signals satiety to the brain. This has been replicated across multiple trials and is well-established. Where things get shakier is in the claim that this replaces bariatric surgery. Metabolic surgery still produces 25-35% total body weight loss on average, with more durable remission of type 2 diabetes than any currently approved GLP-1 therapy (Schauer et al., 2017, New England Journal of Medicine). The two are not equivalent.

What did they get wrong (or right)?

Two errors stand out. First, the drug name. "Temroglutide" does not exist as a pharmaceutical product. The drug being described is semaglutide, sold under the brand names Ozempic and Wegovy. There is a separate drug called teduglutide used for short bowel syndrome, and retatrutide is an investigational GLP-1/GIP/glucagon tri-agonist in trials, but neither matches the description here. This is a meaningful naming error in a video watched 2.2 million times.

Second, "15 kilowatt loss" is clearly a transcription artifact, almost certainly meaning 15 kilograms. But the STEP 1 trial reported percentage body weight loss (approximately 15%), not a flat kilogram figure, because starting weights varied. Citing a flat kilogram number without context can mislead viewers about what they personally might expect.

On the other hand, the GLP-1 mechanism explanation is accurate enough for a general audience, and the weekly injection format is correct. Credit where it is due.

What should you actually know?

Semaglutide at the 2.4mg weekly dose is a legitimate, FDA-approved treatment for chronic weight management in adults with obesity or overweight with a weight-related condition. The results from STEP 1 are real and represent a genuine step forward compared to older anti-obesity medications. However, weight regain after stopping the drug is also well-documented. Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed participants regained about two-thirds of lost weight within a year of stopping treatment.

Bariatric surgery is not going anywhere. For patients with severe obesity and related conditions, the long-term outcomes of procedures like Roux-en-Y gastric bypass still outperform any currently approved medication. GLP-1 drugs and surgery are increasingly being studied as complementary tools, not competing ones. Framing this as an "end" to surgery may discourage patients who genuinely need surgical options from pursuing them.

• Always discuss treatment options with a qualified clinician before making decisions based on social media content.
• If you are currently taking any GLP-1 medication, do not adjust your dose based on viral videos.